Unintentional weight loss with or without an identifiable cause could signal HIV-associated wasting (HIVAW), even in people with undetectable HIV1,2

Timely identification and treatment of HIVAW is important to help restore health and potentially reduce mortality risk3

People with HIVAW experience

5x

more annual hospitalizations


 

2x

more emergency department visits

vs people without HIVAW4

In one study, weight loss of ≥5% in 6 months or ≥3% from baseline was a significant predictor of mortality.6

 

 

Continuous assessment and timely diagnosis of HIVAW can3,4:

 

 

It’s important to assess your patients at each visit for HIVAW or HAWL by:

 

 

Talk to your patients about any concerns they may have about unintentional weight loss or low energy.

Download this list of questions to help start the dialogue.

 

The people depicted on this website are not actual healthcare providers or patients with HIV-associated wasting.

References: 1. Mounzer K, Brunet L, Hsu R, et al. Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. AIDS Res and Human Retroviruses. 2021;37(11)852-861. 2. Siddiqui J, Samuel S, Hayward B, et al. HIV-associated wasting prevalence in the era of modern antiretroviral therapy. AIDS. 2022;36:127-135. 3. Wohlfeiler MB, Weber RP, Brunet L, et al. Incident HIV-associated wasting/low eight is associated with nearly doubled mortality risk in the modern ART era. AIDS Res Hum Retroviruses. 2024; doi.org/10.1089/AID.2023.0113 4. Siddiqui J, Samuel S, Hayward B, et al. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy. J Manag Care Spec Pharm. 2022;20(10):1180-1189. 5. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Med. 2006;7(5):299-310. 6. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr. 2005;40(1):70-76. 7. Siddiqui J, Phillips AL, Freedland ES, Sklar AR, Darkow T, Harley CR. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr Med Res Opin. 2009;25(5):1307-1317. 8. Wanke C, Kotler D, and the HIV Wasting Collaborative Consensus Committee. Collaborative recommendations: the approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr. 2004;37(5):S284-S288. 9. Falutz J. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications. Best Pract Res Clin Endocrinol Metab. 2011;25(3):517-529. 10. Wasserman P, Segal-Maurer S, Wehbeh W, Rubin DS. Wasting disease, chronic immune activation, and inflammation in the HIV-infected patient. Top Clin Nutr. 2011;26(1):14-28. 11. Macallan DC. Wasting in HIV infection and AIDS. J Nutr. 1999;129(1S suppl):238S-242S. 12. Erlandson KM et al. Long-term impact of HIV wasting on physical function. AIDS. 2016;30(3):445-454.